Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Short-term Investments (2018 - 2025)

Historic Short-term Investments for Regen BioPharma (RGBPP) over the last 4 years, with Q1 2025 value amounting to $17733.0.

  • Regen BioPharma's Short-term Investments changed N/A to $17733.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $17733.0, marking a year-over-year change of. This contributed to the annual value of $17733.0 for FY2024, which is 9203.3% down from last year.
  • According to the latest figures from Q1 2025, Regen BioPharma's Short-term Investments is $17733.0.
  • Over the past 5 years, Regen BioPharma's Short-term Investments peaked at $222580.0 during Q3 2023, and registered a low of $17733.0 during Q3 2024.
  • Moreover, its 3-year median value for Short-term Investments was $17733.0 (2024), whereas its average is $68944.8.
  • Over the last 5 years, Regen BioPharma's Short-term Investments had its largest YoY gain of 9203.3% in 2024, and its largest YoY loss of 9203.3% in 2024.
  • Quarter analysis of 3 years shows Regen BioPharma's Short-term Investments stood at $222580.0 in 2023, then plummeted by 92.03% to $17733.0 in 2024, then changed by 0.0% to $17733.0 in 2025.
  • Its Short-term Investments stands at $17733.0 for Q1 2025, versus $17733.0 for Q4 2024 and $17733.0 for Q3 2024.